IONIS PHARMACEUTICALS INC's ticker is IONS and the CUSIP is 462222100. A total of 334 filers reported holding IONIS PHARMACEUTICALS INC in Q2 2021. The put-call ratio across all filers is 0.71 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $341,425 | +4.1% | 7,527 | -5.8% | 0.11% | +7.9% |
Q2 2023 | $327,953 | +5.8% | 7,993 | -7.8% | 0.10% | +6.3% |
Q1 2023 | $309,973 | +96464.8% | 8,673 | +2.0% | 0.10% | -7.8% |
Q4 2022 | $321 | -99.9% | 8,499 | -3.8% | 0.10% | -22.0% |
Q3 2022 | $391,000 | +10.5% | 8,833 | -7.5% | 0.13% | +20.0% |
Q2 2022 | $354,000 | -1.7% | 9,551 | -1.7% | 0.11% | +14.6% |
Q1 2022 | $360,000 | +42.3% | 9,714 | +16.8% | 0.10% | +52.4% |
Q4 2021 | $253,000 | -26.9% | 8,318 | -19.4% | 0.06% | -30.0% |
Q3 2021 | $346,000 | -18.0% | 10,324 | -2.4% | 0.09% | -17.4% |
Q2 2021 | $422,000 | -10.8% | 10,583 | +0.7% | 0.11% | -16.8% |
Q1 2021 | $473,000 | -20.6% | 10,512 | -0.4% | 0.13% | -24.7% |
Q4 2020 | $596,000 | +13.1% | 10,549 | -5.0% | 0.17% | -1.7% |
Q3 2020 | $527,000 | -21.3% | 11,101 | -2.3% | 0.18% | -28.9% |
Q2 2020 | $670,000 | +12.6% | 11,365 | -9.7% | 0.25% | -6.0% |
Q1 2020 | $595,000 | -33.6% | 12,582 | -15.1% | 0.26% | -5.7% |
Q4 2019 | $896,000 | -5.3% | 14,828 | -6.1% | 0.28% | -9.9% |
Q3 2019 | $946,000 | -9.9% | 15,798 | -3.3% | 0.31% | -7.7% |
Q2 2019 | $1,050,000 | -19.5% | 16,338 | +1.6% | 0.34% | -21.4% |
Q1 2019 | $1,305,000 | +46.5% | 16,083 | -2.4% | 0.43% | +36.1% |
Q4 2018 | $891,000 | +2.5% | 16,486 | -2.1% | 0.32% | +14.1% |
Q3 2018 | $869,000 | +24.1% | 16,847 | +0.2% | 0.28% | +17.9% |
Q2 2018 | $700,000 | -11.1% | 16,807 | -5.9% | 0.24% | -10.6% |
Q1 2018 | $787,000 | -11.6% | 17,860 | +1.0% | 0.26% | -10.5% |
Q4 2017 | $890,000 | -4.5% | 17,688 | -3.8% | 0.29% | -6.7% |
Q3 2017 | $932,000 | -1.4% | 18,378 | -1.1% | 0.32% | -4.5% |
Q2 2017 | $945,000 | +30.3% | 18,577 | +3.1% | 0.33% | +23.6% |
Q1 2017 | $725,000 | -12.5% | 18,024 | +4.0% | 0.27% | -16.6% |
Q4 2016 | $829,000 | +75.3% | 17,328 | +34.3% | 0.32% | +73.0% |
Q3 2016 | $473,000 | +55.6% | 12,898 | -1.0% | 0.18% | +48.0% |
Q2 2016 | $304,000 | -39.7% | 13,034 | +4.8% | 0.12% | -44.4% |
Q1 2016 | $504,000 | -28.7% | 12,440 | +9.0% | 0.22% | -33.8% |
Q4 2015 | $707,000 | – | 11,414 | – | 0.34% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Tweedy, Browne Co LLC | 3,510,173 | $159,221,447 | 8.52% |
Bellevue Group AG | 9,233,700 | $418,840,632 | 6.75% |
Deep Track Capital, LP | 2,834,069 | $128,553,370 | 4.96% |
BVF INC/IL | 4,004,613 | $181,649,246 | 4.90% |
Sicart Associates LLC | 203,132 | $9,214,068 | 3.61% |
Camber Capital Management LP | 2,250,000 | $102,060 | 3.36% |
Privium Fund Management B.V. | 228,493 | $10,364,443 | 3.08% |
Orbimed Advisors | 2,169,500 | $98,408,520 | 2.09% |
SECTOR GAMMA AS | 165,616 | $7,512,342 | 1.92% |
TANAKA CAPITAL MANAGEMENT INC | 14,612 | $663 | 1.89% |